Preventive Effect Of Pirarubicin On Recurrence Of Non-muscle Invasive Bladder Cancer After Resection

Background and objectiveBladder cancer is the most common malignancy of the urinary system.According to the extent of cancer cell invasion,the non-muscle invasive bladder cancer and muscle invasive bladder cancer are the two main types.The non-muscle invasive bladder cancer accounted for 75%-85%,in clinical,transurethral bladder tumor Surgery is the most important treatment,but about 70% of patients will undergo recurrence after surgery.Peritoneal perfusion chemotherapy is the most important way to prevent the recurrence of non-muscle invasive bladder cancer.However,at this stage,there is no uniform program for intravesical chemotherapy.In this retrospective clinical study,I selected 160 cases of non-muscle invasive bladder cancer patients from January 2012 to December 2016,who were treated by transurethral resection of bladder tumor,postoperative periodic given pirarubicin.The purpose of the thesis is to investigate the preventive effect and safety of pirarubicin on recurrence of non-muscle invasive bladder cancer after resection.MethodsThe study selected 160 cases of non-muscle invasive bladder cancer patients from January 2012 to December 2016,who were treated by transurethral resection of bladder tumor.In accordance with the principle of random numbers,the patents were divided into 4 groups,which were all given with postoperative periodic administration of pirarubicin and mitomycin intracavitary infusion chemotherapy program,along with regular review and follow-up.The study paid close attention to the complications and recurrence of the patients for two years.Patients underwent transurethral resection of the bladder(80cases): Group I(n = 40)received transurethral resection of the bladder after 24 hours were given with pirarubicin intravesical perfusion program.Group II(n = 40)received transurethral resection of the bladder after 24 hours were given with Mitomycin intravesical perfusion programpatients underwent transurethral resection of the bladder(80 cases): Group A(n = 40)received transurethral resection of the bladder after 1 week of transurethral resection of the bladder were given with pirarubicin intravesical perfusion regimen.Group B(n = 40)received transurethral resection of the bladder after 1 week of transurethral resection of the bladder were given with mitomycin intravesical perfusion regimen.Results(1)Bladder irrigation within 24 hours①Patients who had intravesical instillation within 24 hours were all followed up.,The follow-up time was(2.1 ~ 3.5)years,(2.8 ± 0.3)years in average.Neither of the groups had death cases.The recurrence rate of the two groups was 15.00%,the recurrence rate was 25.00%(P <0.05).The comparison between group I and group II enjoyed great statistical meaning.(P <0.05)②short-term bladder irritation in group I was 22.50%,while short-term bladder irritation in group II was 27.50%,There was no significant difference between the two groups(P> 0.05).③The incidence of hematuria in group I was 17.50%.while the short-term bladder irritation in group II was 22.50%,and there was no significant difference between the two groups(P> 0.05).④There were no significant abnormalities such as wound infection,bladder perforation or other serious adverse reactions in the blood,urine,liver function and renal function of the two groups of patients(2)bladder irrigation after 1week①The recurrence rate was 25.00% in group A and 27.50% in group B,there was no significant difference between the two groups(P> 0.05).②short-term bladder irritation in group A was 22.50%,while short-term bladder irritation in group B was 27.50%,there was no significant difference between the two groups(P> 0.05).③The incidence of hematuria in group A was 17.50%,while the short-term bladder irritation in group B was 22.50%,There was no significant difference between the two groups(P> 0.05).④There were no significant abnormalities such as wound infection,bladder perforation or other serious adverse reactions in the blood,urine,liver function and renal function of the two groups of patients.(3)Bladder irrigation within 24 hours and after 1week①(P <0.05).The recurrence rate of early and conventional perfusion of mitomycin was not statistically significant(P> 0.05).The recurrence rate of early and conventional perfusion of pirarubicin was statistically significant(P <0.05).②The early and conventional perfusion of pirarubicin,early and conventional perfusion of mitomycin,and the incidence of hematuria were not statistically significant(P> 0.05).Conclusions(1)Pilocarpine after resection of intravesical instillation of adverse reactions compared with mitomycin,has no significant difference,which can be tolerated by general patients(2)Comparing with intravesical instillation of pirarubicin and 24 hours after operation,the clinical effect of intravesical instillation chemotherapy was more significant than the one that within 24 hours after pirarubicin surgery.After 1 week of pirarubicin There was no significant difference in the treatment of intravesical instillation compared with mitomycin.It indicated that intravesical instillation of intraperitoneal infusion within 24 hours after pirarubicin was a very effective and safe method for the prevention of recurrence of postoperative tumor.